Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ADK | P55263 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 9/20 | 0.41 |
| ▸ | CA2 | P00918 | 9/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 3/20 | 0.40 |
| ▸ | CA9 | Q16790 | 3/20 | 0.40 |
| ▸ | PYGB | P11216 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | GRK6 | P43250 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL582023 | 1.00 | PNP (0.44) | PNPGSK3BTSHRADKCA1 | |
| SCHEMBL1434439 | 1.00 | PNP (0.44) | PNPGSK3BTSHRADKCA1 | |
| SCHEMBL38256 | 0.77 | TSHR (0.46) | GSK3BTSHRADKCA1CA2 | |
| SCHEMBL4704343 | 0.77 | TSHR (0.46) | GSK3BTSHRADKCA1CA2 | |
| SCHEMBL4278638 | 0.77 | TSHR (0.46) | GSK3BTSHRADKCA1CA2 | |
| SCHEMBL7198908 | 0.77 | TSHR (0.46) | GSK3BTSHRADKCA1CA2 | |
| SCHEMBL11289015 | 0.77 | TSHR (0.46) | GSK3BTSHRADKCA1CA2 | |
| SCHEMBL319584 | 0.77 | TSHR (0.46) | GSK3BTSHRADKCA1CA2 | |
| SCHEMBL7030562 | 0.77 | TSHR (0.46) | GSK3BTSHRADKCA1CA2 | |
| SCHEMBL375915 | 0.77 | TSHR (0.46) | GSK3BTSHRADKCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250268993-A1 | ALKALINE PHOSPHATE-BASED ONCOLOGY TREATMENTS | THERIVA BIOLOGICS, INC. | 2025-08-28 | — | — | US | claimed |
| US-12318434-B2 | Alkaline phosphate-based oncology treatments | THERIVA BIOLOGICS, INC. (US) | 2025-06-03 | — | — | US | claimed |
| US-20220202914-A1 | ALKALINE PHOSPHATE-BASED ONCOLOGY TREATMENTS | THERIVA BIOLOGICS, INC. | 2022-06-30 | — | — | US | claimed |
| EP-3965805-A1 | ALKALINE PHOSPHATE-BASED ONCOLOGY TREATMENTS | Synthetic Biologics, Inc. (US) | 2022-03-16 | — | — | EP | claimed |
| CN-113993541-A | Alkaline phosphatase-based oncology therapy | 合成生物制品有限公司 | 2022-01-28 | — | — | CN | claimed |
| WO-2020227263-A1 | ALKALINE PHOSPHATE-BASED ONCOLOGY TREATMENTS | SYNTHETIC BIOLOGICS, INC. (US) | 2020-11-12 | — | — | WO | claimed |
| US-20200163995-A1 | PHARMACEUTICAL KIT AND USES THEREOF | JOHNPRO BIOTECH INC. (TW) | 2020-05-28 | — | — | US | claimed |
| WO-2019029351-A1 | PHARMACEUTICAL KIT AND USES THEREOF | JOHNPRO BIOTECH INC. (CN) | 2019-02-14 | — | — | WO | claimed |
| US-20140031288-A1 | NOVEL COMPOSITION FOR TUMOR GROWTH CONTROL | ERASMUS UNIVERSITY MEDICAL CENTER (NL) | 2014-01-30 | — | — | US | claimed |
| EP-2007370-B1 | NOVEL COMPOSITION FOR TUMOR GROWTH CONTROL | UNIV ERASMUS MEDICAL CT (NL) | 2013-12-18 | — | — | EP | claimed |
| US-20080026362-A1 | Three-dimensional culture containing human articular chondrocytes with induced terminal differentiation changes, and preparation process and uses of the same | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2008-01-31 | — | — | US | claimed |
| WO-2007114697-A1 | NOVEL COMPOSITION FOR TUMOR GROWTH CONTROL | ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM (NL) | 2007-10-11 | — | — | WO | claimed |
| US-7279175-B2 | Stent coated with a sustained-release drug delivery and method for use thereof | PSIVIDA INC. (US) | 2007-10-09 | — | — | US | claimed |
| WO-2007016037-A2 | METHODS FOR TRANS-DIFFERENTIATING CELLS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2007-02-08 | — | — | WO | claimed |
| US-6932777-B2 | Prophylactic and therapeutic treatment of the ductal epithelium of a mammary gland for cancer | JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE (US) | 2005-08-23 | — | — | US | claimed |
| EP-1429774-A2 | STENT COATED WITH A SUBSTAINED-RELEASE DRUG DELIVERY | Control Delivery Systems, Inc. (US) | 2004-06-23 | — | — | EP | claimed |
| US-6656918-B2 | Contacting the ductal epithelium of the exocrine gland with epithelium destroying agents such as ethanol and vaccinia virus | JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE | 2003-12-02 | — | — | US | claimed |
| US-20030108588-A1 | Stent coated with a sustained-release drug delivery and method for use thereof | EyePoint Pharmaceuticals, Inc. | 2003-06-12 | — | — | US | claimed |
| WO-2003024455-A2 | STENT COATED WITH A SUSTAINED-RELEASE DRUG DELIVERY AND METHOD FOR USE THEREOF | CONTROL DELIVERY SYSTEMS, INC. (US) | 2003-03-27 | — | — | WO | claimed |
| EP-0594667-B1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO NEURON INC (US) | 2001-09-19 | — | — | EP | claimed |